The Prostate Cancer Puzzle: Fitting the Players into Place
Medivation Inc.'s strong Phase III survival data for prostate cancer drug MDV-3100 raise two questions. First, can the prostate cancer market support so many players? And second, with the bar for survival edging higher, is there a place for Phase III prostate cancer trials with alternate endpoints, like Exelixis Inc.'s pain-focused study of cabozantinib?
Analysts say yes on both counts.
While many prostate cancer drugs are starting to come onto the market, they are largely targeting different stages of the disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter